Filing Flows › Teladoc Health (TDOC) › Guidance history
Teladoc Health (TDOC) guidance history: what it guided and what it reported
Teladoc Health gave guidance in 3 earnings releases on file since Apr 29, 2026. Of 2 guided periods since reported, it met or beat its own guidance twice (100%). Revenue: 2 of 2, on average +1.0% against the guided midpoint. Its releases raised guidance once and lowered it once.
Revenue
Met or beat 2 of 2 periods (0 above, 2 within, 0 below).
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q4 2026 | $569M–$615M (Oct 28, 2026) | — | to be reported | — |
| Q3 2026 | $569M–$609M (Jul 29, 2026) | $605M | within the range | +2.7% |
| Q2 2026 | $597M–$626M (Apr 29, 2026) | $607M | within the range | -0.8% |
| FY2026 | $2.5B–$2.6B (Apr 29, 2026) → lowered $2.4B–$2.4B (Jul 29, 2026) → raised $2.4B–$2.4B (Oct 28, 2026) | — | to be reported | — |
EPS
This line is not in the statements Filing Flows reads, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q4 2026 | −$0.23–−$0.03 (Oct 28, 2026) | — | to be reported | — |
| Q3 2026 | −$0.30–−$0.20 (Jul 29, 2026) | — | — | — |
| Q2 2026 | −$0.30–−$0.20 (Apr 29, 2026) | — | — | — |
| FY2026 | −$1.05–−$0.75 (Apr 29, 2026) → raised −$1.00–−$0.75 (Jul 29, 2026) → raised −$0.95–−$0.75 (Oct 28, 2026) | — | to be reported | — |
Free cash flow
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $130M–$170M (Apr 29, 2026) → reaffirmed $130M–$170M (Jul 29, 2026) → reaffirmed $135M–$165M (Oct 28, 2026) | — | to be reported | — |
Interest expense
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $5.4B (Apr 29, 2026) | — | to be reported | — |
Stock-based compensation
Every guided period is still to be reported.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| FY2026 | $14.6B (Apr 29, 2026) | — | to be reported | — |
Adjusted EBITDA
The guide is on an adjusted basis that the GAAP statements do not show, so there is no reported figure to hold it to.
| Period | Guided (and how it moved) | Reported | Result | vs midpoint |
|---|---|---|---|---|
| Q4 2026 | $74.0M–$100M (Oct 28, 2026) | — | to be reported | — |
| Q3 2026 | $62.0M–$74.0M (Jul 29, 2026) | — | — | — |
| Q2 2026 | $55.0M–$67.0M (Apr 29, 2026) | — | — | — |
| FY2026 | $267M–$306M (Apr 29, 2026) → reaffirmed $271M–$303M (Jul 29, 2026) → raised $277M–$303M (Oct 28, 2026) | — | to be reported | — |
The latest quarter
Teladoc Health, Q3 2026: revenue $605M (-3% year over year), operating margin -4.6%, net loss $26.9M, operating cash flow $106M. The chart follows the revenue to costs, profit and cash.
Questions
Does Teladoc Health beat its guidance?
Teladoc Health gave guidance in 3 earnings releases on file since Apr 29, 2026. Of 2 guided periods since reported, it met or beat its own guidance twice (100%). Revenue: 2 of 2, on average +1.0% against the guided midpoint.
How often does Teladoc Health raise guidance?
Its earnings releases raised guidance once and lowered it once since Apr 29, 2026.
Each guided period is held to the last guidance given before its figures were reported; a single figure counts as in line within 1% (0.25 pts for a rate). Reported figures are GAAP, from the company's filings; adjusted guidance shows its moves only.